It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Immunodominance of antibodies targeting non-neutralizing epitopes and the high level of somatic hypermutation within germinal centers (GCs) required for most HIV broadly neutralizing antibodies (bnAbs) are major impediments to the development of an effective HIV vaccine. Rational protein vaccine design and non-conventional immunization strategies are potential avenues to overcome these hurdles. Here, we report using implantable osmotic pumps to continuously deliver a series of epitope-targeted immunogens to rhesus macaques over the course of six months to prime and elicit antibody responses against the conserved fusion peptide (FP). GC responses and antibody specificities were tracked longitudinally using lymph node fine-needle aspirates and electron microscopy polyclonal epitope mapping (EMPEM), respectively, to show antibody responses to the FP/N611 glycan hole region were primed, although exhibited limited neutralization breadth. Application of cryoEMPEM delineated key residues for on-target and off-target responses that can drive the next round of structure-based vaccine design.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 The Scripps Research Institute, Department of Integrative Structural and Computational Biology, La Jolla, USA (GRID:grid.214007.0) (ISNI:0000 0001 2219 9231); The Scripps Research Institute, Center for HIV/AIDS Vaccine Development (CHAVD), La Jolla, USA (GRID:grid.214007.0) (ISNI:0000 0001 2219 9231)
2 The Scripps Research Institute, Center for HIV/AIDS Vaccine Development (CHAVD), La Jolla, USA (GRID:grid.214007.0) (ISNI:0000 0001 2219 9231); La Jolla Institute for Immunology, La Jolla, USA (GRID:grid.185006.a) (ISNI:0000 0004 0461 3162)
3 The Scripps Research Institute, Center for HIV/AIDS Vaccine Development (CHAVD), La Jolla, USA (GRID:grid.214007.0) (ISNI:0000 0001 2219 9231); Emory University, Division of Microbiology and Immunology, Emory National Primate Research Center, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502)
4 Emory University, Division of Microbiology and Immunology, Emory National Primate Research Center, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502)
5 Duke University Medical Center Durham, Duke Human Vaccine Institute and Department of Surgery, Durham, USA (GRID:grid.189509.c) (ISNI:0000 0001 0024 1216)
6 University of Southampton, School of Biological Sciences, Southampton, UK (GRID:grid.5491.9) (ISNI:0000 0004 1936 9297)
7 Massachusetts Institute of Technology, Koch Institute for Integrative Cancer Research, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786)
8 The Scripps Research Institute, Center for HIV/AIDS Vaccine Development (CHAVD), La Jolla, USA (GRID:grid.214007.0) (ISNI:0000 0001 2219 9231); The Scripps Research Institute, Department of Immunology and Microbiology, La Jolla, USA (GRID:grid.214007.0) (ISNI:0000 0001 2219 9231)
9 The Scripps Research Institute, Center for HIV/AIDS Vaccine Development (CHAVD), La Jolla, USA (GRID:grid.214007.0) (ISNI:0000 0001 2219 9231); Massachusetts Institute of Technology, Koch Institute for Integrative Cancer Research, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786)
10 The Scripps Research Institute, Center for HIV/AIDS Vaccine Development (CHAVD), La Jolla, USA (GRID:grid.214007.0) (ISNI:0000 0001 2219 9231); University of Southampton, School of Biological Sciences, Southampton, UK (GRID:grid.5491.9) (ISNI:0000 0004 1936 9297)
11 The Scripps Research Institute, Center for HIV/AIDS Vaccine Development (CHAVD), La Jolla, USA (GRID:grid.214007.0) (ISNI:0000 0001 2219 9231); La Jolla Institute for Immunology, La Jolla, USA (GRID:grid.185006.a) (ISNI:0000 0004 0461 3162); San Diego, Division of Infectious Disease and Global Public Health, Department of Medicine, University of California, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)